Company Continues its Expansion, Education, and Placement of its Leading Hemp-Derived Supplement Brand, PlusCBD Oil™, in the Natural Products Industry
LAS VEGAS, NV–(Marketwired – July 18, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), preeminent supplier and manufacturer of hemp-derived CBD oil bulk and consumer products, today announced that its industry-dominating brand of hemp-derived cannabidiol (CBD) oil finished products, PlusCBD Oil™, will be exhibited at the 2017 Natural Products Association Midwest Mid-American Health Organization (MAHO) Expo and Summer Splash on July 21-23, 2017, at The Hilton Columbus at Easton in Columbus, Ohio. The Company enters its third year attending at this widely attended regional natural products trade show as a Diamond Plus Sponsor.
As one of the largest regional shows focusing on independent retailers, MAHO’s mission is to advocate for the rights of consumers to have access to products that will maintain and improve their health, and for the rights of retailers and suppliers to sell these products. CV Sciences believes that independent retailers have been the lifeblood of pioneering the hemp-derived CBD category, and the Company continues to focus on expansion of the placement of its quality-assured PlusCBD Oil™ line through its dedication to providing sales tools, marketing support, and consistent education to its retailers and their customers.
“As nationwide popularity of phytocannabinoids and hemp extracts continues to be mainstreamed, we believe it is imperative to educate our retailers on the nuanced nature of this category and ingredient,” states Stuart Tomc, VP of Human Nutrition at CV Sciences. “Since our PlusCBD Oil™ brand launched into the natural products industry 3 years ago, MAHO has been a true partner of CV Sciences, understanding the tremendous value the hemp plant has to offer, and continuing to give us an incredible platform to educate forward-thinking retailers on the most exciting ingredient to hit the shelves in decades. We are thrilled to be able to showcase our growing line of products and look forward to giving attendees the opportunity to attend our lecture in order to learn more about what CV Sciences has been doing to bring hemp products back to the United States.”
VISIT BOOTH 19: CV Sciences invites attendees to visit Booth 19 to learn more about its industry-dominating brand of hemp-derived cannabidiol (CBD) products. Also, CV Sciences will be offering exclusive trade show discounts, giveaways, and show specials to retailers attending the show.
SPONSORED DINNER PRESENTATION: Join the CV Sciences team for an interactive presentation, “The Cannabis Disruption: Bringing Hemp Back” on Friday, July 21st, 2017, at 5pm. Co-presented by Stuart Tomc, VP of Human Nutrition and Josh Hendrix, Director of Business Development, Domestic Production for CV Sciences, the presentation will cover how CV Sciences demonstrates Full Traceability – From Seed to Shelf™, the importance of proper quality control measures to ensure safety and efficacy of its products, and what the Company has invested to bring hemp research forward and to secure the future of hemp in the United States.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.